BMO Cuts Halozyme (HALO) to Market Perform Following FDA's Request for More Info on HyQ Application

An analyst at BMO Capital downgraded shares of Halozyme Therapeutics (NASDAQ: HALO) from Outperform to Market Perform Monday morning. The analyst's price target was lowered from $13 to $9.

Halozyme shares are down a whopping 25 percent at last check following earlier news of a request for more info on the company's HyQ Biologics application. The stock last traded at $8.47.

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• BMO Capital Reiterates Outperform Rating on Workday (WDAY)